Survival benefit of anlotinib in T790M-positive non-small-cell lung cancer patients with acquired osimertinib resistance: A multicenter retrospective study and exploratory in vitro study.

Cancer Med · 2023 · PMC10469739 · PMID 37387596

Europe PMC DOI

hedged sentence

0.0870

closest p · 1.7× alpha

0.0870

boldest claim

The sentences

showed a trendp = 0.087so close (0.05 < p ≤ 0.1)

Subgroup analysis showed a trend of more benefits from the anlotinib‐based therapy than the bevacizumab‐based therapy in terms of PFS (HR: 0.63, p = 0.087) and OS (HR: 0.52, p = 0.063).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.